certara - CERT
CERT
Close Chg Chg %
11.37 0.34 2.99%
Closed Market
11.71
+0.34 (2.99%)
Volume: 870.24K
Last Updated:
Dec 12, 2024, 4:00 PM EDT
Company Overview: certara - CERT
CERT Key Data
| Open $11.30 | Day Range 11.21 - 11.79 |
| 52 Week Range 9.41 - 19.87 | Market Cap $1.83B |
| Shares Outstanding 160.98M | Public Float 111.34M |
| Beta 1.53 | Rev. Per Employee N/A |
| P/E Ratio N/A | EPS -$0.19 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 1.31M |
CERT Performance
| 1 Week | 7.93% | ||
| 1 Month | 17.57% | ||
| 3 Months | 6.94% | ||
| 1 Year | -31.12% | ||
| 5 Years | N/A |
CERT Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
11
Full Ratings ➔
About certara - CERT
Certara, Inc. engages in the provision of software and technology-enabled services for drug developers. It offers cell and gene therapy, clinical pharmacology, complex biologics, decision analytics and modeling, drug development and regulatory strategy, and model-based analysis services. The company was founded on June 27, 2017, and is headquartered in Radnor, PA.
CERT At a Glance
Certara, Inc.
4 Radnor Corporate Center
Radnor, Pennsylvania 19087
| Phone | 1-415-237-8772 | Revenue | 354.34M | |
| Industry | Packaged Software | Net Income | -55,357,000.00 | |
| Sector | Technology Services | 2023 Sales Growth | 5.569% | |
| Fiscal Year-end | 12 / 2024 | Employees | 1,391 | |
| View SEC Filings |
CERT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 7.89 |
| Price to Book Ratio | 2.686 |
| Price to Cash Flow Ratio | 33.783 |
| Enterprise Value to EBITDA | 40.768 |
| Enterprise Value to Sales | 8.068 |
| Total Debt to Enterprise Value | 0.104 |
CERT Efficiency
| Revenue/Employee | 254,735.442 |
| Income Per Employee | -39,796.549 |
| Receivables Turnover | 3.80 |
| Total Asset Turnover | 0.226 |
CERT Liquidity
| Current Ratio | 2.616 |
| Quick Ratio | 2.616 |
| Cash Ratio | 1.807 |
CERT Profitability
| Gross Margin | 47.353 |
| Operating Margin | 3.967 |
| Pretax Margin | -15.562 |
| Net Margin | -15.623 |
| Return on Assets | -3.53 |
| Return on Equity | -5.206 |
| Return on Total Capital | -4.116 |
| Return on Invested Capital | -4.068 |
CERT Capital Structure
| Total Debt to Total Equity | 28.485 |
| Total Debt to Total Capital | 22.17 |
| Total Debt to Total Assets | 19.076 |
| Long-Term Debt to Equity | 28.196 |
| Long-Term Debt to Total Capital | 21.945 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Certara - CERT
Collapse All in section
| All values USD millions. | 2020 | 2021 | 2022 | 2023 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| 243.53M | 286.10M | 335.64M | 354.34M | |
Sales Growth
| +16.79% | +17.48% | +17.32% | +5.57% | |
Cost of Goods Sold (COGS) incl D&A
| 140.62M | 152.47M | 175.74M | 186.55M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 42.75M | 45.12M | 52.47M | 56.07M | |
Depreciation
| 2.44M | 2.13M | 1.73M | 1.55M | |
Amortization of Intangibles
| 40.31M | 42.98M | 50.74M | 54.52M | |
COGS Growth
| +18.56% | +8.42% | +15.26% | +6.15% | |
Gross Income
| 102.91M | 133.64M | 159.91M | 167.79M | |
Gross Income Growth
| +14.46% | +29.86% | +19.66% | +4.93% | |
Gross Profit Margin
| +42.26% | +46.71% | +47.64% | +47.35% |
| 2020 | 2021 | 2022 | 2023 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 127.33M | 106.03M | 124.02M | 153.74M | |
Research & Development
| 19.64M | 20.38M | 28.20M | 34.17M | |
Other SG&A
| 107.68M | 85.65M | 95.81M | 119.56M | |
SGA Growth
| +81.14% | -16.72% | +16.96% | +23.96% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | 14.96M | 4.33M | 54.83M | |
EBIT after Unusual Expense
| (24.42M) | 12.65M | 31.56M | (40.77M) | |
Non Operating Income/Expense
| (465.00K) | 812.00K | 4.97M | 8.55M | |
Non-Operating Interest Income
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| 25.30M | 16.84M | 17.77M | 22.92M | |
Interest Expense Growth
| -9.67% | -33.44% | +5.56% | +28.94% | |
Gross Interest Expense
| 25.30M | 16.84M | 17.77M | 22.92M | |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (50.18M) | (3.38M) | 18.75M | (55.14M) | |
Pretax Income Growth
| -448.37% | +93.27% | +655.70% | -394.02% | |
Pretax Margin
| -20.61% | -1.18% | +5.59% | -15.56% | |
Income Tax
| (784.00K) | 9.89M | 4.02M | 214.00K | |
Income Tax - Current - Domestic
| 1.99M | 2.25M | 5.22M | 7.96M | |
Income Tax - Current - Foreign
| 4.63M | 8.83M | 10.32M | 8.78M | |
Income Tax - Deferred - Domestic
| (3.34M) | (5.57M) | (8.98M) | (13.79M) | |
Income Tax - Deferred - Foreign
| (4.06M) | 4.39M | (2.53M) | (2.73M) | |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (49.40M) | (13.27M) | 14.73M | (55.36M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (49.40M) | (13.27M) | 14.73M | (55.36M) | |
Net Income Growth
| -453.41% | +73.14% | +211.04% | -475.79% | |
Net Margin Growth
| -20.28% | -4.64% | +4.39% | -15.62% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (49.40M) | (13.27M) | 14.73M | (55.36M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (49.40M) | (13.27M) | 14.73M | (55.36M) | |
EPS (Basic)
| -0.3229 | -0.0885 | 0.0939 | -0.3483 | |
EPS (Basic) Growth
| -469.49% | +72.59% | +206.10% | -470.93% | |
Basic Shares Outstanding
| 152.98M | 149.84M | 156.88M | 158.94M | |
EPS (Diluted)
| -0.3229 | -0.0885 | 0.0924 | -0.3483 | |
EPS (Diluted) Growth
| -469.49% | +72.59% | +204.41% | -476.95% | |
Diluted Shares Outstanding
| 152.98M | 149.84M | 159.35M | 158.94M | |
EBITDA
| 18.33M | 72.72M | 88.36M | 70.13M | |
EBITDA Growth
| -70.03% | +296.66% | +21.51% | -20.64% | |
EBITDA Margin
| +7.53% | +25.42% | +26.33% | +19.79% |
Snapshot
| Average Recommendation | OVERWEIGHT | Average Target Price | 14.278 | |
| Number of Ratings | 11 | Current Quarters Estimate | 0.122 | |
| FY Report Date | 12 / 2024 | Current Year's Estimate | 0.426 | |
| Last Quarter’s Earnings | 0.13 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.43 | Next Fiscal Year Estimate | 0.503 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 9 | 8 | 10 | 10 |
| Mean Estimate | 0.12 | 0.12 | 0.43 | 0.50 |
| High Estimates | 0.13 | 0.13 | 0.45 | 0.55 |
| Low Estimate | 0.12 | 0.11 | 0.42 | 0.48 |
| Coefficient of Variance | 3.35 | 7.04 | 2.25 | 5.02 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 5 | 4 | 4 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 6 | 6 | 7 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Overweight | Overweight | Overweight |
SEC Filings for Certara - CERT
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Certara - CERT
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Jul 3, 2024 | Robert P. Aspbury PRESIDENT, SCIENTIFIC SOFTWARE | 289,314 | Payment of exercise price or tax liability by delivering/withholding secs incident to the receipt/exercise/vesting pursuant to Rule 16b-3 Non-derivative transaction at $13.85 per share | 4,006,998.90 |
| Jun 4, 2024 | Daniel Corcoran SVP and General Counsel | 29,777 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 4, 2024 | Daniel Corcoran SVP and General Counsel | 23,822 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Jun 4, 2024 | Rona Anhalt Chief Human Resources Officer | 21,440 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 24, 2024 | Eran Broshy Director | 11,928 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 24, 2024 | Nancy Killefer Director | 11,928 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 24, 2024 | Nancy Killefer Director | 24,161 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 24, 2024 | Rosemary A. Crane Director | 11,928 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 24, 2024 | Rosemary A. Crane Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 24, 2024 | Rosemary A. Crane Director | 17,987 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 24, 2024 | James E. Cashman Director | 11,928 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 24, 2024 | James E. Cashman Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 24, 2024 | James E. Cashman Director | 456,512 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 24, 2024 | Matthew M. Walsh Director | 185,631 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 24, 2024 | Eran Broshy Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 24, 2024 | Eran Broshy Director | 23,023 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 24, 2024 | Cynthia L. Collins Director | 11,928 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| May 24, 2024 | Cynthia L. Collins Director | N/A | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 24, 2024 | Cynthia L. Collins Director | 24,161 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 0.00 |
| May 24, 2024 | Matthew M. Walsh Director | 11,928 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |